Go Back MCP-1/CCL2

Product Detail

A DNA sequence encoding the human MCP-1 protein sequence (containing the signal peptide sequence, and the mature human MCP-1 sequence) was expressed in modified human 293 cells.

Monocyte chemotactic protein-1 (MCP-1) belongs to the chemokine family. Chemokines are small secreted molecules containing 4 conserved cysteine residues and 2 disulfide linkages. The first two cysteine residues of chemokine molecules may be in one of the following configurations, CC or CXC and this defines the two major chemokine sub-families. MCP-1 is a CC chemokine and its recent designation is chemokine ligand 2, (CCL2). MCP-1 is expressed by monocytes, dendritic cells, vascular endothelial cells, smooth muscle cells, glomerular mesangial cells, osteoblastic cells, and human pulmonary type-2-like epithelial cells in response to the cytokines IL-1, TNF-a, IFN-g, as well as bacterial or viral products and mitogens. MCP-1 exhibits chemotactic activity for monocytes/macrophages, basophils, T lymphocytes, particularly memory T cells and natural killer cells and neural stem cells. Elevated levels of MCP-1 are detected during inflammation and immune responses. MCP-1 activity is also important in wound healing as shown by delayed wound repair in MCP-1deficient mice. MCP-1 is implicated in the pathogenesis of disease states that involve monocyte/macrophage infiltrates, such as psoriasis, rheumatoid arthritis and recruitment of monocytes to the arterial wall in atherosclerosis. In addition to its chemotactic function, MCP-1 also induces the expression of IL-10 from macrophages, which favours a TH2 immune response. MCP-1 is a glycopeptide containing one potential N-linked glycosylation site. The extent of MCP-1 glycosylation influences its chemotactic potency and half-life in vivo. The glycosylated form of MCP-1 exhibits lower specific chemotactic activity for both lymphocytes and monocytes than the non-glycosylated form, however the non-glycosylated form rapidly loses activity at 37°C. For a review of the role of MCP-1 in inflammatory disorders of the lung please refer to Rose CE Jr, et al. (2003) Microcirculation. 10(3-4): 273-88.